Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that Wockhardt Bio AG, a subsidiary of the Company, has incorporated three new Wholly Owned Subsidiaries Wockhardt Swiss AG (Switzerland), Wockhardt Suisse USA Holding Corporation (USA) and Wockhardt Suisse USA LLC (USA). Consequent to the incorporation, Wockhardt Swiss AG, Wockhardt Suisse USA Holding Corporation and Wockhardt Suisse USA LLC have become Step-Down Subsidiaries of the Company
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt Limited announced that its subsidiary, Wockhardt Bio AG, has incorporated three new wholly owned subsidiaries: Wockhardt Swiss AG in Switzerland, Wockhardt Suisse USA Holding Corporation in the USA, and Wockhardt Suisse USA LLC in the USA. As a result of this incorporation, these three new entities have become step-down subsidiaries of Wockhardt Limited. The move appears to be part of a global corporate restructuring to streamline the company's international operations across Europe and the United States. No financial details, capital investment, or business rationale figures were disclosed in the filing.
This is an internal corporate restructuring with no immediate direct impact on shareholders. It may signal Wockhardt's intent to expand or reorganise its global pharmaceutical operations, but investors should watch for further clarity on the strategic purpose and any capital commitments involved.